Exciting New Data for TNBC Therapies

Panelists discuss how:
Rrecent ESMOEuropean Society for Medical Oncology presentations revealed transformative findings for triple-negative breast cancer (TNBC) management. The ASCENT-03 and TROPION-Breast02 studies demonstrated significant efficacy of ADCantibody-drug conjugate-based and novel combination regimens, improving survival and tolerability. Panelists interpret the clinical implications, highlighting where these agents may fit in treatment algorithms. They stress the importance of real-world data and multidisciplinary coordination to ensure broad access and equitable benefits across diverse patient populations.